Background In the 5 years that have passed since the publication of the 2018 International
Consensus Statement on Allergy and Rhinology: Allergic Rhinitis (ICAR‐Allergic Rhinitis …

Background Critical examination of the quality and validity of available allergic rhinitis (AR)
literature is necessary to improve understanding and to appropriately translate this …

Objective Allergic rhinitis (AR) is one of the most common diseases affecting adults. It is the
most common chronic disease in children in the United States today and the fifth most …

■ Abstract The safety and efficacy of intranasal corticosteroids (INCs) are well established
for the management of allergic rhinitis, rhinosinusitis, and nasal polyps. As seen in …

Cite this as: GJ Rodrigo and H. Neffen, Clinical & Experimental Allergy, 2011 (41) 160–170.
Summary Background Although previous data suggest that intranasal fluticasone furoate …

Intranasal corticosteroids (INSs) are the most efficacious medication for the treatment of
allergic rhinitis. In 2006, the Joint Task Force of the American College of Allergy, Asthma …

Context Use of systemic corticosteroids (CSs) may induce adverse cardiometabolic
alterations, potentially leading to obesity and metabolic syndrome (MetS). Although …

Objectives To address concerns related to the safety profile of both Food and Drug
Administration (FDA)–approved and non–FDA-approved intranasal corticosteroid (INCS) …

Allergic rhinitis is a common condition that frequently coexists with asthma and atopic
dermatitis. It is commonly treated with intranasal corticosteroids which may increase the …

Background Budesonide is a potent corticosteroid commonly prescribed for management of
inflammation in chronic rhinosinusitis (CRS). The standard for prescribing budesonide is via …